Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...

Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug

Annexon (NASDAQ:ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026 ...